About TICOVAC™ (Tick-borne encephalitis vaccine)
Pfizer’s TBE vaccine, marketed under the brand names FSME-Immun® and TicoVac™ in Europe, and TICOVAC™ in the U.S., is developed using a master ‘seed’ virus that is similar to the TBE virus found in nature.7 It is able to induce neutralizing antibodies against the natural TBE virus, as the sequence and structure of the virus subtype match those found in nature.8
In clinical trials, the safety and immunogenicity of TICOVAC™ were assessed across two age groups (1-15 years of age and >16 years of age).6 In these studies, seropositivity rates were 99.5% in 1-15 year olds and 98.7-100% in adults >15 years following three doses.* 6,9,10 Clinical studies demonstrated that TICOVAC™ was generally well-tolerated with no unexpected adverse events or vaccine-related serious adverse events observed.11,12 The most common adverse reactions across both age groups were local tenderness, headache, local pain, fever, restlessness, fatigue, and muscle pain.11,12 Real-world studies from Austria have shown that the vaccine is 96-98.7% effective in people who have received at least three doses of the vaccine.13,14